Imatinib and GIST: 18FDG-PET Scan
{"Image DocumentName": "Imatinib and GIST: 18FDG-PET Scan", "Image ImageDescription": "[slide 30] Imatinib and GIST: 18FDG-PET Scan1. PET scan using 18fluorodeoxyglucose (FDG) images the biological activity of GISTs. Retention of the FDG tracer records metabolic tumour activity in relation to normal tissues. After 4 weeks of therapy with imatinib, this patient showed a marked attenuation of signal on the PET scan. FDG-PET scan may provide early clinical evidence of biological response to imatinib for patients with malignant GISTs. Reference: 1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344: Multiple liver and upper abdominal 18FDG-accumulating metastases. A marked decrease in 18FDG uptake 4 weeks after starting imatinib. Joensuu et al. N Engl J Med. 2001;344:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}